| A Phase 1 Clinical Study in Healthy Participants (NCT07584876) | Shanghai Argo Biopharmaceutical Co., Ltd. | 2026-05-29 |
| A Phase 1 Study of Single-Dose BW-50218 in Healthy Chinese Participants (NCT07577479) | Shanghai Argo Biopharmaceutical Co., Ltd. | 2026-05-18 |
| A Phase 1 Clinical Study of BW-20805-2-1001 in Healthy Participants (NCT07528053) | Shanghai Argo Biopharmaceutical Co., Ltd. | 2026-04-28 |
| Study of BW-50218 in Healthy Participants (NCT07401472) | Shanghai Argo Biopharmaceutical Co., Ltd. | 2026-03-12 |
| A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B (NCT07135349) | Shanghai Argo Biopharmaceutical Co., Ltd. | 2025-09-02 |
| A Study to Assess the Safety and Effects of the Investigational Drug BW-40202 in Healthy Volunteers (NCT06917482) | Shanghai Argo Biopharmaceutical Co., Ltd. | 2025-06-30 |
| A Phase 2 in Adult Subjects With Hereditary Angioedema (NCT06846398) | Shanghai Argo Biopharmaceutical Co., Ltd. | 2025-02-28 |
| A Study of BW-20507 in Chinese Healthy Subjects and Subjects With Chronic Hepatitis B (NCT07595159) | Shanghai Argo Biopharmaceutical Co., Ltd. | 2024-06-24 |
| A Study in Patients With Mixed Dyslipidemia (NCT06497127) | Shanghai Argo Biopharmaceutical Co., Ltd. | 2024-02-28 |